<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34944747</PMID><DateRevised><Year>2021</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-&#x3b2; but Higher Levels of IL-1&#x3b1; and TGF-&#x3b2;.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1931</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines9121931</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">SARS-CoV-2 infection induces in some patients a condition called long-COVID-19, herein post-COVID-19 (PC), which persists for longer than the negative oral-pharyngeal swab. One of the complications of PC is pulmonary fibrosis. The purpose of this study was to identify blood biomarkers to predict PC patients undergoing pulmonary fibrosis.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We analyzed blood samples of healthy, anti-SARS-CoV-2 vaccinated (VAX) subjects and PC patients who were stratified according to the severity of the disease and chest computed tomography (CT) scan data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The inflammatory C reactive protein (CRP), complement complex C5b-9, LDH, but not IL-6, were higher in PC patients, independent of the severity of the disease and lung fibrotic areas. Interestingly, PC patients with ground-glass opacities (as revealed by chest CT scan) were characterized by higher plasma levels of IL-1&#x3b1;, CXCL-10, TGF-&#x3b2;, but not of IFN-&#x3b2;, compared to healthy and VAX subjects. In particular, 19 out of 23 (82.6%) severe PC and 8 out of 29 (27.6%) moderate PC patients presented signs of lung fibrosis, associated to lower levels of IFN-&#x3b2;, but higher IL-1&#x3b1; and TGF-&#x3b2;.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found that higher IL-1&#x3b1; and TGF-&#x3b2; and lower plasma levels of IFN-&#x3b2; could predict an increased relative risk (RR = 2.8) of lung fibrosis-like changes in PC patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colarusso</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy (DIFARMA), University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maglio</LastName><ForeName>Angelantonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1874-1686</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Salerno, Baronissi Campus, Via S. Allende, 84081 Baronissi, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terlizzi</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy (DIFARMA), University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitale</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Salerno, Baronissi Campus, Via S. Allende, 84081 Baronissi, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molino</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Respiratory Division, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Aldo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacy (DIFARMA), University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vatrella</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8265-3037</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Salerno, Baronissi Campus, Via S. Allende, 84081 Baronissi, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Rosalinda</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacy (DIFARMA), University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword><Keyword MajorTopicYN="N">pulmonary fibrosis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34944747</ArticleId><ArticleId IdType="pmc">PMC8698335</ArticleId><ArticleId IdType="doi">10.3390/biomedicines9121931</ArticleId><ArticleId IdType="pii">biomedicines9121931</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Colarusso C., Terlizzi M., Pinto A., Sorrentino R. A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. Br. J. Pharmacol. 2020;177:4866&#x2013;4872. doi: 10.1111/bph.15154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15154</ArticleId><ArticleId IdType="pmc">PMC7300552</ArticleId><ArticleId IdType="pubmed">32497257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I.K.D., Hodeib S., Korol C., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570. doi: 10.1126/science.abd4570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffman H., Zhang Y., Dorgham K., Philippot Q., Rosain J., B&#xe9;ziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long Covid. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.F., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y.C., Yu C.J., Chang S.C., Galvin J.R., Liu H.M., Hsiao C.H., Kuo P.H., Chen K.Y., Franks T.J., Huang K.M., et al. Pulmonary sequelae inconvalescent patients after severe acute respiratory syndrome: Evaluation with thin-section CT. Radiology. 2005;236:1067&#x2013;1075. doi: 10.1148/radiol.2363040958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2363040958</ArticleId><ArticleId IdType="pubmed">16055695</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F., Ye T., Sun P., Gui S., Liang B., Li L., Zheng D., Wang J., Hesketh R.L., Yang L., et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19) Radiology. 2020;295:715&#x2013;721. doi: 10.1148/radiol.2020200370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020200370</ArticleId><ArticleId IdType="pmc">PMC7233367</ArticleId><ArticleId IdType="pubmed">32053470</ArticleId></ArticleIdList></Reference><Reference><Citation>Polidoro R.B., Hagan R.S., de Santis Santiago R., Schmidt N.W. Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. Front. Immunol. 2020;11:1626. doi: 10.3389/fimmu.2020.01626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01626</ArticleId><ArticleId IdType="pmc">PMC7344249</ArticleId><ArticleId IdType="pubmed">32714336</ArticleId></ArticleIdList></Reference><Reference><Citation>Smilowitz N.R., Kunichoff D., Garshick M., Shah B., Pillinger M., Hochman J.S., Berger J.S. C-reactive protein and clinical outcomes in patients with COVID-19. Eur. Heart J. 2021;42:2270&#x2013;2279. doi: 10.1093/eurheartj/ehaa1103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa1103</ArticleId><ArticleId IdType="pmc">PMC7928982</ArticleId><ArticleId IdType="pubmed">33448289</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalkanen J., Hollm&#xe9;n M., Jalkanen S. Interferon beta-1a for COVID-19: Critical importance of the administration route. Crit. Care. 2020;24:335. doi: 10.1186/s13054-020-03048-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03048-5</ArticleId><ArticleId IdType="pmc">PMC7290144</ArticleId><ArticleId IdType="pubmed">32532353</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttmann M., Merzyn C., Rieckmann P. Interferon-&#x3b2; induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J. Neuroimmunol. 2004;156:195&#x2013;203. doi: 10.1016/j.jneuroim.2004.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2004.07.016</ArticleId><ArticleId IdType="pubmed">15465611</ArticleId></ArticleIdList></Reference><Reference><Citation>Terlizzi M., Molino A., Colarusso C., Donovan C., Imitazione P., Somma P., Aquino R.P., Hansbro P.M., Pinto A., Sorrentino R. Activation of the Absent in Melanoma 2 Inflammasome in Peripheral Blood Mononuclear Cells From Idiopathic Pulmonary Fibrosis Patients Leads to the Release of Pro-Fibrotic Mediators. Front. Immunol. 2018;9:670. doi: 10.3389/fimmu.2018.00670.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00670</ArticleId><ArticleId IdType="pmc">PMC5895962</ArticleId><ArticleId IdType="pubmed">29675024</ArticleId></ArticleIdList></Reference><Reference><Citation>Borthwick L.A. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin. Immunopathol. 2016;38:517&#x2013;534. doi: 10.1007/s00281-016-0559-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-016-0559-z</ArticleId><ArticleId IdType="pmc">PMC4896974</ArticleId><ArticleId IdType="pubmed">27001429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli G., Colafrancesco S., Emmi G., Imazio M., Lopalco G., Maggio M.C., Sota J., Dinarelloh C.A. Interleukin 1&#x3b1;: A comprehensive review on the role of IL-1&#x3b1; in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun. Rev. 2021;20:102763. doi: 10.1016/j.autrev.2021.102763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102763</ArticleId><ArticleId IdType="pubmed">33482337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigdelioglu R., Hamanaka R.B., Meliton A.Y., O&#x2019;Leary E., Witt L.J., Cho T., Sun K., Bonham C., Wu D., Woods P.S., et al. Transforming growth factor (TGF)-&#x3b2; promotes de Novo serine synthesis for collagen production. J. Biol. Chem. 2016;291:27239&#x2013;27251. doi: 10.1074/jbc.M116.756247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.756247</ArticleId><ArticleId IdType="pmc">PMC5207151</ArticleId><ArticleId IdType="pubmed">27836973</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho T., Krammer F., Iwasaki A. The first 12 months of COVID-19: A timeline of immunological insights. Nat. Rev. Immunol. 2021;21:245&#x2013;256. doi: 10.1038/s41577-021-00522-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00522-1</ArticleId><ArticleId IdType="pmc">PMC7958099</ArticleId><ArticleId IdType="pubmed">33723416</ArticleId></ArticleIdList></Reference><Reference><Citation>Tale S., Ghosh S., Meitei S.P., Kolli M., Garbhapu A.K., Pudi S. Post-COVID-19 pneumonia pulmonary fibrosis. QJM Int. J. Med. 2020;113:837&#x2013;838. doi: 10.1093/qjmed/hcaa255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcaa255</ArticleId><ArticleId IdType="pmc">PMC7454835</ArticleId><ArticleId IdType="pubmed">32814978</ArticleId></ArticleIdList></Reference><Reference><Citation>DiPiazza A.T., Graham B.S., Ruckwardt T.J. T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochem. Biophys. Res. Commun. 2021;538:211&#x2013;217. doi: 10.1016/j.bbrc.2020.10.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.060</ArticleId><ArticleId IdType="pmc">PMC7584424</ArticleId><ArticleId IdType="pubmed">33190827</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung J.Y., Thone M.N., Kwon J.Y. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv. Drug Deliv. Rev. 2021;170:1&#x2013;25. doi: 10.1016/j.addr.2020.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.12.011</ArticleId><ArticleId IdType="pmc">PMC7759095</ArticleId><ArticleId IdType="pubmed">33359141</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmstr&#xf6;m J., Lindberg H., Lindberg C., Bratt C., Wieslander E., Delander E., S&#xe4;rnstrand B., Burns J.S., Mose-Larsen P., Fey S., et al. Transforming growth factor-beta 1 specifically induce proteins involved in the myofibroblast contractile apparatus. Mol. Cell. Proteom. 2004;3:466&#x2013;477. doi: 10.1074/mcp.M300108-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M300108-MCP200</ArticleId><ArticleId IdType="pubmed">14766930</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>